Trospium氯在膀胱过动症的管理。

文章的细节

引用

复制到剪贴板

•罗夫纳西文

Trospium氯在膀胱过动症的管理。

药。2004;64(21):2433 - 46所示。doi: 10.2165 / 00003495-200464210-00005。

PubMed ID

15482001 (在PubMed

]

文摘

Trospium氯是一种口服有效,季铵化合物与antimuscarinic活动。它与高亲和力结合具体和毒蕈碱的受体M(1),(2)和(3),但不是烟碱,胆碱能受体。亲水性和不交叉在大量正常血脑屏障,因此,具有最小的中枢抗胆碱能活性。血浆trospium氯浓度达到峰值后约5 - 6小时口服,饭前应该发生并发食物摄入明显减少trospium生物利用度。氯化Trospium经历微不足道的肝代谢的细胞色素P450系统;很少有代谢药物的相互作用。虽然trospium氯剂量调整基于年龄或性别出现不必要的,这种调整可能需要有严重肾功能损害的患者。膀胱过动症患者的直接比较研究表明氯化trospium至少oxybutynin和tolterodine一样有效。安慰剂对照研究也证实trospium氯的效果的改善尿动态参数;小规模,noncomparative研究记录重要trospium chloride-induced改善反射神经性膀胱功能障碍的患者,术后膀胱刺激和放射性膀胱炎; and observational studies including >10,000 patients have also revealed favourable findings for trospium chloride, including a marked decrease in incontinence episodes and substantial improvement in health-related quality of life. Trospium chloride is generally well tolerated, and significantly more so than immediate-release oxybutynin. The most frequent adverse events, occurring in >1% of trospium chloride-treated patients, are dry mouth, dyspepsia, constipation, abdominal pain and nausea. Available for many years in several countries outside North America, trospium chloride is likely to develop an important role in the management of overactive bladder following its approval in the US on 28 May 2004.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Trospium	毒蕈碱的乙酰胆碱受体M1	蛋白质	人类	未知的	拮抗剂	细节